Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 1, 2012, Pages 47-53

  Sorbe, Bengt ^a   Graflund, Marianne ^a   Horvath, György ^b   Swahn, Marie ^b   Boman, Karin ^c   Bangshöj, René ^d   Lood, Margareta ^d   Malmström, Henric ^e  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carboplatin; Docetaxel; Ovarian cancer; Weekly administration

Indexed keywords

CARBOPLATIN; DOCETAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG WITHDRAWAL; EDEMA; EPIPHORA; FATIGUE; FEMALE; GASTRITIS; HEARTBURN; HOARSENESS; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84858182909     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318234fa3a     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Case Base No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
3. Copeland LJ, Bookman M, Trimble E, Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol. 2003;90:S1-S7.
4. Safra T, Menczer J, Bernstein RM, et al. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol. 2009;114:215-218.
5. Sehouli J, Stengel D, Mustea A, et al. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol. 2008;61:243-250. (Pubitemid 350160322)
6. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
7. Kavanagh JJ. Docetaxel in the treatment of ovarian cancer. Oncology. 2002;16:73-81.
8. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer. 2003;89:S9-S15. (Pubitemid 38067998)
9. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682-1691. (Pubitemid 39585637)
10. Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007;105:358-364. (Pubitemid 46613899)
11. Tinker AV, Gebski V, Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel - ANZGOG 02-01. Gynecol Oncol. 2007;104:647-653. (Pubitemid 46240256)
12. Gupta D, Owers RL, Kim M, et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol. 2009;113:327-330.
13. Safra T, Bernstein Molho R, Menzcher J, et al. A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism. Chemotherapy. 2009;55:298-302.
14. Terauchi F, Hirano T, Taoka H, et al. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Int J Clin Oncol. 2003;8:348-351. (Pubitemid 38036089)
15. Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004;95:624-631. (Pubitemid 39592531)
16. Komiyama S, Tsuji H, Asai S, et al. A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol. 2005;6:299-302. (Pubitemid 40874044)
17. Calvert AH, Newell DR, Gunbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756. (Pubitemid 19272848)
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
19. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253. (Pubitemid 23008970)
20. Rustin GJ, Marples M, Nelstrop AE. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004;10:3919-3926. (Pubitemid 38697628)
21. National Institutes of Health. Common Terminology Criteria for Adverse Events (Version 3.0). Washington, DC: National Institutes of Health; 2003.
22. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17:771-776. (Pubitemid 47063333)
23. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154-159.
24. Winter WE III, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:83-89.
25. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol. 2010;18:A-LBA1 [Abstract].
26. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642-1649.
27. Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504-507. (Pubitemid 36885989)
28. Oishi T, Kigawa J, Fujiwara K, et al. A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol. 2003;90:421-424. (Pubitemid 36952038)